Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1521-1530

  Kuo, Po Lin ^a,b   Hung, Jen Yu ^a,b   Huang, Shau Ku ^c   Chou, Shah Hwa ^b   Cheng, Da En ^a   Jong, Yuh Jyh ^a,b   Hung, Chih Hsing ^a,b   Yang, Chih Jen ^b   Tsai, Ying Ming ^b   Hsu, Ya Ling ^a   Huang, Ming Shyan ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; GLYCOPROTEIN P 15095; INHIBITOR OF DIFFERENTIATION 3; INTERLEUKIN 10; LACTOSE; TRANSCRIPTION FACTOR FOXP3;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; LUNG CANCER; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; BRONCHI; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CLONAL ANERGY; DENDRITIC CELLS; GALECTIN 1; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INHIBITOR OF DIFFERENTIATION PROTEINS; INTERLEUKIN-10; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION;

EID: 79251546096     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002940     Document Type: Article

References (42)

1. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59: 225-249.
2. Robson, N. C., S. Hoves, E. Maraskovsky, and M. Schnurr. 2010. Presentation of tumour antigens by dendritic cells and challenges faced. Curr. Opin. Immunol. 22: 137-144.
3. Liu, Q., C. Zhang, A. Sun, Y. Zheng, L. Wang, and X. Cao. 2009. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182: 6207-6216.
4. Bluth, M. J., L. C. Zaba, D. Moussai, M. Suárez-Fariñas, H. Kaporis, L. Fan, K. C. Pierson, T. R. White, A. Pitts-Kiefer, J. Fuentes-Duculan, et al. 2009. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J. Invest. Dermatol. 129: 2451-2462.
5. Curiel, T. J., P. Cheng, P. Mottram, X. Alvarez, L. Moons, M. Evdemon-Hogan, S. Wei, L. Zou, I. Kryczek, G. Hoyle, et al. 2004. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64: 5535-5538.
6. Wilcox, R. A., D. A. Wada, S. C. Ziesmer, S. F. Elsawa, N. I. Comfere, A. B. Dietz, A. J. Novak, T. E. Witzig, A. L. Feldman, M. R. Pittelkow, and S. M. Ansell. 2009. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114: 2936-2944.
7. Dhodapkar, M. V., K. M. Dhodapkar, and A. K. Palucka. 2008. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 15: 39-50.
8. Rek, A., E. Krenn, and A. J. Kungl. 2009. Therapeutically targeting protein-glycan interactions. Br. J. Pharmacol. 157: 686-694.
9. Ilarregui, J. M., and G. A. Rabinovich. 2010. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation 17: 157-160.
10. Demydenko, D., and I. Berest. 2009. Expression of galectin-1 in malignant tumors. Exp. Oncol. 31: 74-79.
11. Ding, Y. M., J. H. Dong, L. L. Chen, and H. D. Zhang. 2009. Increased expression of galectin-1 is associated with human oral squamous cell carcinoma development. Oncol. Rep. 21: 983-987.
12. Cindolo, L., G. Benvenuto, P. Salvatore, R. Pero, G. Salvatore, V. Mirone, D. Prezioso, V. Altieri, C. B. Bruni, and L. Chiariotti. 1999. Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int. J. Cancer 84: 39-43.
13. Wu, M. H., T. M. Hong, H. W. Cheng, S. H. Pan, Y. R. Liang, H. C. Hong, W. F. Chiang, T. Y. Wong, D. B. Shieh, A. L. Shiau, et al. 2009. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol. Cancer Res. 7: 311-318.
14. Gandhi, M. K., G. Moll, C. Smith, U. Dua, E. Lambley, O. Ramuz, D. Gill, P. Marlton, J. F. Seymour, and R. Khanna. 2007. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110: 1326-1329.
15. Rubinstein, N., M. Alvarez, N. W. Zwirner, M. A. Toscano, J. M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O. L. Podhajcer, and G. A. Rabinovich. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251.
16. Juszczynski, P., J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104: 13134-13139.
17. DeCicco, K. L., T. Tanaka, F. Andreola, and L. M. De Luca. 2004. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway. Carcinogenesis 25: 1805-1812.
18. Huang, L. J., S. X. Chen, Y. Huang, W. J. Luo, H. H. Jiang, Q. H. Hu, P. F. Zhang, and H. Yi. 2006. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 54: 87-94.
19. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
20. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser, and C. H. June. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
21. Gerlini, G., A. Tun-Kyi, C. Dudli, G. Burg, N. Pimpinelli, and F. O. Nestle. 2004. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 165: 1853-1863.
22. Beckebaum, S., X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati. 2004. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 10: 7260-7269.
23. Kee, B. L. 2009. E and ID proteins branch out. Nat. Rev. Immunol. 9: 175-184.
24. Hacker, C., R. D. Kirsch, X. S. Ju, T. Hieronymus, T. C. Gust, C. Kuhl, T. Jorgas, S. M. Kurz, S. Rose-John, Y. Yokota, and M. Zenke. 2003. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. 4: 380-386.
25. Gottfried, E., M. Kreutz, and A. Mackensen. 2008. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 19: 65-77. (Pubitemid 351200062)
26. Bharadwaj, U., M. Li, R. Zhang, C. Chen, and Q. Yao. 2007. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res. 67: 5479-5488. (Pubitemid 46997289)
27. He, J., and L. G. Baum. 2006. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab. Invest. 86: 578-590.
28. Matarrese, P., A. Tinari, E. Mormone, G. A. Bianco, M. A. Toscano, B. Ascione, G. A. Rabinovich, and W. Malorni. 2005. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 280: 6969-6985.
29. Ilarregui, J. M., D. O. Croci, G. A. Bianco, M. A. Toscano, M. Salatino, M. E. Vermeulen, J. R. Geffner, and G. A. Rabinovich. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10: 981-991.
30. Fulcher, J. A., M. H. Chang, S. Wang, T. Almazan, S. T. Hashimi, A. U. Eriksson, X. Wen, M. Pang, L. G. Baum, R. R. Singh, and B. Lee. 2009. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J. Biol. Chem. 284: 26860-26870.
31. Zeni, E., L. Mazzetti, D. Miotto, N. Lo Cascio, P. Maestrelli, P. Querzoli, M. Pedriali, E. De Rosa, L. M. Fabbri, C. E. Mapp, and P. Boschetto. 2007. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur. Respir. J. 30: 627-632.
32. Hsia, C. Y., T. I. Huo, S. Y. Chiang, M. F. Lu, C. L. Sun, J. C. Wu, P. C. Lee, C. W. Chi, W. Y. Lui, and S. D. Lee. 2007. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 33: 208-212.
33. Mustea, A., D. Könsgen, E. I. Braicu, C. Pirvulescu, P. Sun, D. Sofroni, W. Lichtenegger, and J. Sehouli. 2006. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 26: 1715-1718.
34. Duluc, D., M. Corvaisier, S. Blanchard, L. Catala, P. Descamps, E. Gamelin, S. Ponsoda, Y. Delneste, M. Hebbar, and P. Jeannin. 2009. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 125: 367-373.
35. Sica, A., A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. van Damme, and A. Mantovani. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164: 762-767. (Pubitemid 30043699)
36. Dercamp, C., K. Chemin, C. Caux, G. Trinchieri, and A. P. Vicari. 2005. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res. 65: 8479-8486.
37. Kaporis, H. G., E. Guttman-Yassky, M. A. Lowes, A. S. Haider, J. Fuentes-Duculan, K. Darabi, J. Whynot-Ertelt, A. Khatcherian, I. Cardinale, I. Novitskaya, et al. 2007. Human basal cell carcinoma is associated with Foxp3 + T cells in a Th2 dominant microenvironment. J. Invest. Dermatol. 127: 2391-2398.
38. Mustea, A., E. I. Braicu, D. Koensgen, S. Yuan, P. M. Sun, F. Stamatian, W. Lichtenegger, F. C. Chen, R. Chekerov, and J. Sehouli. 2009. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 45: 8-11.
39. Lech-Maranda, E., J. Bienvenu, A. S. Michallet, R. Houot, T. Robak, B. Coiffier, and G. Salles. 2006. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur. Cytokine Netw. 17: 60-66.
40. Kee, B. L., R. R. Rivera, and C. Murre. 2001. Id3 inhibits B lymphocyte progenitor growth and survival in response to TGF-beta. Nat. Immunol. 2: 242-247.
41. Spits, H., F. Couwenberg, A. Q. Bakker, K. Weijer, and C. H. Uittenbogaart. 2000. Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre- DC2. J. Exp. Med. 192: 1775-1784.
42. Gratchev, A., J. Kzhyshkowska, S. Kannookadan, M. Ochsenreiter, A. Popova, X. Yu, S. Mamidi, E. Stonehouse-Usselmann, I. Muller-Molinet, L. Gooi, and S. Goerdt. 2008. Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J. Immunol. 180: 6553-6565.